Skip to main content

Silexion Therapeutics Corp 8-K, filed Nov 16, 2026

Silexion Therapeutics Corp (SLXN)

8-K 2026-11-16 For: 2026-11-16
View Original
Added on November 16, 2026

About this 8-K

Silexion Therapeutics Corp filed this 8-K on November 16, 2026.

Silexion Therapeutics Corp dosed its first patient with SIL204 on September 30, 2026 in a Phase 2/3 pancreatic cancer trial at Tel Aviv Sourasky Medical Center. Cash and cash equivalents were $4.8 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits